In vivo CAR-T therapy shows promise for multiple sclerosis

A promising clinical trial published on September 3, 2026, in The New England Journal of Medicine reveals that a lentivirus-based in vivo CAR-T therapy can improve symptoms for individuals with multiple sclerosis and other autoimmune conditions. The trial involved 16 participants who received a single injection, resulting in the generation of CAR T cells that effectively targeted and depleted harmful autoantibodies produced by B cells, known to attack healthy tissues in autoimmune diseases. The results show significant improvements in symptoms, marking a notable advancement in treatment options for these conditions.

This trial builds on existing knowledge about CAR-T therapies, which have traditionally been used to treat blood cancers. In vivo CAR-T therapy represents a shift in approach, allowing for the production of immune cells within the body rather than extracting and modifying them in a laboratory. This method is considered faster and more cost-effective compared to conventional ex vivo therapies.

The success of this trial serves as a proof-of-concept for the potential of in vivo CAR-T therapy to treat autoimmune diseases. Careful monitoring of participants over a six-month period followed the injection of the lentivirus. Researchers, including lead investigator Dai-Shi Tian, noted that the treatment led to a depletion of autoantibodies and an increase in the production of healthy B cells that do not attack the body’s own tissues. Participants reported improvements in motor and cognitive functions, along with reductions in fatigue, showcasing the therapy's potential benefits.

The broader implications of this study extend to the field of immunology and the treatment of autoimmune diseases. The ability to reset the immune system through in vivo CAR-T therapy could offer new hope for patients suffering from conditions that currently have limited treatment options. As researchers continue to explore this innovative approach, the findings may pave the way for more effective therapies that can enhance the quality of life for individuals with autoimmune disorders.

Looking forward, the trial results encourage further research and larger clinical trials to validate the efficacy and safety of in vivo CAR-T therapy for a wider population. The excitement surrounding these findings indicates a significant step toward developing novel treatments for autoimmune diseases. As scientists refine this approach, the potential for in vivo CAR-T therapy to transform the landscape of treatment for multiple sclerosis and similar conditions remains a topic of great interest in the medical community.